NUO THERAPEUTICS INC NEW (AURX) earnings
AURX earnings moved a median of 0.00% by the close. Quarterly and annual AURX reports and results, each read against the price at its own news timestamp. Back to the AURX overview →
17 measured AURX earnings events.
Where these AURX earnings landedvs 11 measured AURX earnings reactions
| Middle 50% of AURX earnings reactions | -2.21% to +0.02% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 11 |
Point-in-time · zero look-ahead
Half of the 11 AURX earnings events with a measured close landed between -2.21% and +0.02%; 36% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Nuo Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update | Press release | +0.00% | +0.02% | |
| Form 10-Q Nuo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.02% | |
| Form 10-Q Nuo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | — | — | |
| Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update | Press release | — | — | |
| Form 10-K Nuo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +1.55% | |
| Form 10-Q Nuo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -15.93% | |
| Form 10-Q Nuo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -4.38% | |
| Form 10-Q Nuo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | — | +12.11% | |
| Form 10-K Nuo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.00% | |
| Form NT 10-K Nuo Therapeutics, Inc. For: Dec 31 | SEC filing · Form NT | +0.00% | +0.00% | |
| Form 10-Q Nuo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | — | — | |
| Form 10-Q Nuo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -0.04% | |
| Form 10-Q Nuo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | — | — | |
| Form 10-K Nuo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | — | — | |
| Form NT 10-K Nuo Therapeutics, Inc. For: Dec 31 | SEC filing · Form NT | — | — | |
| Form 10-Q Nuo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.02% | -5.45% | |
| Form NT 10-Q Nuo Therapeutics, Inc. For: Sep 30 | SEC filing · Form NT | +0.00% | +0.00% |
Keep exploring
More AURX: analyst actions → · SEC filings → · AURX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Regen Biopharma, Inc. Common (RGBP) | 85 | 0.00% | 36% |
| UCB SA UNSP/ADR (UCBJY) | 85 | +0.00% | 51% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 84 | 0.00% | 14% |
| Knight Therapeutics Inc (GUD_TSE) | 84 | 0.00% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.